DC-CIK联合埃克替尼一线治疗晚期NSCLC的疗效分析

目的 DC-CIK(DC细胞即树突状细胞,CIK细胞即细胞因子诱导的杀伤细胞)联合埃克替尼一线治疗晚期非小细胞肺癌(NSCLC)患者的早期临床疗效评估。方法 18名晚期NSCLC患者接受DC-CIK联合埃克替尼治疗,埃克替尼为每日3次口服,每次125mg,疗程为3个月,在服用埃克替尼治疗过程中接受DC-CIK生物免疫治疗1~2个疗程。若出现不能耐受的不良反应或疾病进展时停用。结果其中疾病控制率为77.7%(14例),客观有效率为33.3%(6例),所有患者KPS评分均较治疗前有所升高,临床症状均得到不同程度缓解,部分患者外周血肿瘤标记物水平下降显著。共6例出现I度药物相关不良反应,为皮疹、腹泻和恶心。结论 DC-CIK联合埃克替尼在一线治疗晚期NSCLC患者中早期临床效果显著,且不良反应轻微。

Observation on the efficacy of DC-CIK combined with icotinib in treatment of elderly advanced non-small cell lung cancer patients

Objective To analyze early clinical efficacy of autologous cytokine-induced dendritic cells （DC） and killer cells （CIK） combined with icotinib in treatment of elderly advanced non-small cell lung cancer patients. Methods Eighteen non-small cell lung cancer patients were treated with autologous CIK and DC for once or twice daily in combination with 125mg icotinib three times a day for a course of 3 months and the treatment would be interrupted once the disease deterioriated or patients could not stand the toxic side effects. Results The effective rate was 77.7 %（14/18）, and the objective response rate was 33.3%（6/18）. The level of g2S in all patients was increased and clinical symptoms improved. The level of tumor maker in most patients was decreased. The main toxicity was erythra, diarrhea and nausea.Conclusions The early therapeutic effects of DC-CIK combined with icotinib as the first-line treatment was effective on advanced non-small cell lung cancer patients with light adverse reaction.